Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Vir Biotechnology Inc (NASDAQ: VIR) closed at $6.39 down -0.78% from its previous closing price of $6.44. In other words, the price has decreased by -$0.78 from its previous closing price. On the day, 1.89 million shares were traded. VIR stock price reached its highest trading level at $6.5 during the session, while it also had its lowest trading level at $6.25.
Ratios:
For a deeper understanding of Vir Biotechnology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.25 and its Current Ratio is at 7.25. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In the most recent recommendation for this company, Evercore ISI on September 03, 2025, initiated with a Outperform rating and assigned the stock a target price of $12.
On August 27, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $14.
JP Morgan Downgraded its Overweight to Neutral on January 29, 2024, whereas the target price for the stock was revised from $23 to $9.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 25 ’25 when SVF Endurance (Cayman) Ltd sold 235,971 shares for $6.38 per share. The transaction valued at 1,505,495 led to the insider holds 14,110,209 shares of the business.
SVF Endurance (Cayman) Ltd sold 227,803 shares of VIR for $1,400,783 on Nov 24 ’25. The 10% Owner now owns 14,346,180 shares after completing the transaction at $6.15 per share. On Nov 25 ’25, another insider, SVF Endurance (Cayman) Limited, who serves as the 10% Owner of the company, bought 1,251,303 shares for $6.44 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 889008896 and an Enterprise Value of 482670944. For the stock, the TTM Price-to-Sale (P/S) ratio is 52.73 while its Price-to-Book (P/B) ratio in mrq is 1.12. Its current Enterprise Value per Revenue stands at 28.628 whereas that against EBITDA is -0.944.
Stock Price History:
The Beta on a monthly basis for VIR is 1.33, which has changed by -0.19723618 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.16. The 50-Day Moving Average of the stock is 11.96%, while the 200-Day Moving Average is calculated to be 10.14%.
Shares Statistics:
For the past three months, VIR has traded an average of 1.51M shares per day and 1610600 over the past ten days. A total of 139.02M shares are outstanding, with a floating share count of 93.09M. Insiders hold about 33.09% of the company’s shares, while institutions hold 54.23% stake in the company. Shares short for VIR as of 1763078400 were 10992709 with a Short Ratio of 7.28, compared to 1760486400 on 10940671. Therefore, it implies a Short% of Shares Outstanding of 10992709 and a Short% of Float of 12.72.
Earnings Estimates
. The current assessment of Vir Biotechnology Inc (VIR) involves the perspectives of 8.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.45 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$3.02 and -$3.62 for the fiscal current year, implying an average EPS of -$3.46. EPS for the following year is -$2.92, with 9.0 analysts recommending between -$2.3 and -$3.63.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $1.42M this quarter.It ranges from a high estimate of $3.9M to a low estimate of $240k. As of. The current estimate, Vir Biotechnology Inc’s year-ago sales were $12.37MFor the next quarter, 7 analysts are estimating revenue of $2.35M. There is a high estimate of $4.5M for the next quarter, whereas the lowest estimate is $240k.
A total of 9 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $10M, while the lowest revenue estimate was $4.73M, resulting in an average revenue estimate of $6.45M. In the same quarter a year ago, actual revenue was $74.2MBased on 9 analysts’ estimates, the company’s revenue will be $9.66M in the next fiscal year. The high estimate is $18.1M and the low estimate is $1M.
